Bionano Genomics (BNGO) Cash from Investing Activities (2017 - 2026)

Bionano Genomics has disclosed Cash from Investing Activities across 10 years of filings, most recently posting $5.5 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $5.5 million, up 138.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 million (down 44.4% YoY), and the FY2025 annual result was -$12.7 million, down 117.26% from the prior year.
• Cash from Investing Activities came in at $5.5 million for Q1 2026 at Bionano Genomics, up from $4.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $47.6 million in Q1 2024 to a low of -$55.4 million in Q4 2023.
• The 5-year median for Cash from Investing Activities is $8.0 million (2022), against an average of $10.2 million.
• Across the five-year window, Cash from Investing Activities surged 133283.33% in 2022 and slumped 576.94% in 2023, its largest moves.
• Bionano Genomics' Cash from Investing Activities stood at $11.6 million in 2022, then plunged by 576.94% to -$55.4 million in 2023, then soared by 105.41% to $3.0 million in 2024, then jumped by 33.77% to $4.0 million in 2025, then soared by 36.12% to $5.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $5.5 million (Q1 2026), $4.0 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.